Search
Short QT syndrome
go.drugbank.com/conditions/DBCOND0022435Drugs: IsoprenalineSynonyms: Genetic short QT syndrome, Genetic short QT syndrome (disorder)Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Categories: Dopamine D2 Receptor Antagonists, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-oneResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalOn March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1,2,4-Triazine-6-carbonitrile, 2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-, 2-[3,5-Dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrilePalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.
Mixtures: REAMPLA®, REAMPLA®Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexHelium
go.drugbank.com/drugs/DB09155ApprovedInvestigationalVet approvedIt is also used as an analytical reagent in diagnostic/imaging tests to detect respiratory function of the patient. … Helium is a second most abundant chemical element in the universe with symbol He and atomic number 2.
Mixtures: Oxygen In Helium Mix, Oxygen In Helium MixtureCongenital neutropenia
go.drugbank.com/conditions/DBCOND0020521Drugs: FilgrastimSynonyms: Infantile genetic agranulocytosis, Severe infantile genetic neutropeniaEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: Drugs Used in Diabetes, P-glycoprotein substratesTagatose
go.drugbank.com/drugs/DB04936InvestigationalAdditionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes. … It is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener.
Categories: Compounds used in a research, industrial, or household settingSynonyms: D-tag, D-lyxo-hex-2-ulosePemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Categories: Heterocyclic Compounds, 1-Ring